{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:03Z","timestamp":1793931783180,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032745","name":"Gilead Sciences Italia","doi-asserted-by":"publisher","award":["Grant for data publication \"Espressione e significato clinico-biologico di TROP2 nel pancancer\" 2022\/2023"],"award-info":[{"award-number":["Grant for data publication \"Espressione e significato clinico-biologico di TROP2 nel pancancer\" 2022\/2023"]}],"id":[{"id":"10.13039\/100032745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01523-w","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:03:24Z","timestamp":1781514204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Giulia","family":"Notini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Galbardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo M.","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"De Micheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Licata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Barreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Callari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Zanibelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patan\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Chiavassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Raza","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"C\u00f3rtes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Dugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"1523_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744","author":"P Lombardi","year":"2023","unstructured":"Lombardi, P. et al. Overview of trop-2 in cancer: from pre-clinical studies to future directions in clinical settings. Cancers https:\/\/doi.org\/10.3390\/cancers15061744 (2023).","journal-title":"Cancers"},{"key":"1523_CR2","doi-asserted-by":"crossref","unstructured":"Lipinski M., Parks D. R., Rouse R. V., Herzenberg L. A. Human Trophoblast Cell-Surface Antigens Defined by Monoclonal Antibodies (Choriocarcinoma\/Fetal Cells\/Fluorescence-Activated Cell-Sorter). Vol 78. https:\/\/www.pnas.org (1981).","DOI":"10.1073\/pnas.78.8.5147"},{"key":"1523_CR3","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/OTT.S162447","volume":"12","author":"S Zaman","year":"2019","unstructured":"Zaman, S., Jadid, H., Denson, A. C. & Gray, J. E. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 12, 1781\u20131790 (2019).","journal-title":"Onco Targets Ther."},{"key":"1523_CR4","doi-asserted-by":"crossref","unstructured":"Shvartsur A., Bonavida B. Trop2 and Its Overexpression in Cancers: Regulation and Clinical\/ Therapeutic Implications. Vol 6. www.impactjournals.com\/Genes&Cancer (2015).","DOI":"10.18632\/genesandcancer.40"},{"key":"1523_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan, L. P. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J. Histochem. Cytochem. 59, 701\u2013710 (2011).","journal-title":"J. Histochem. Cytochem."},{"key":"1523_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113379","author":"C Bosi","year":"2023","unstructured":"Bosi, C. et al. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. Eur. J. Cancer https:\/\/doi.org\/10.1016\/j.ejca.2023.113379 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1523_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola, M. et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32, 222\u2013233 (2013).","journal-title":"Oncogene"},{"key":"1523_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep33658","author":"P Zeng","year":"2016","unstructured":"Zeng, P. et al. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci. Rep. Nat. Publ. Group. https:\/\/doi.org\/10.1038\/srep33658 (2016).","journal-title":"Sci. Rep. Nat. Publ. Group."},{"key":"1523_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed, Y. Y. Sacituzumab Govitecan: first approval. Drugs 80, 1019\u20131025 (2020).","journal-title":"Drugs"},{"key":"1523_CR10","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo, H. S. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 402, 1423\u20131433 (2023).","journal-title":"Lancet."},{"key":"1523_CR11","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima, D. et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol. Cancer Ther. 20, 2329\u20132340 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1523_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","volume":"156","author":"C Han","year":"2020","unstructured":"Han, C. et al. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecol. Oncol. 156, 430\u2013438 (2020).","journal-title":"Gynecol. Oncol."},{"key":"1523_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/1878-0261.12627","volume":"14","author":"E Perrone","year":"2020","unstructured":"Perrone, E. et al. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Mol. Oncol. 14, 645\u2013656 (2020).","journal-title":"Mol. Oncol."},{"key":"1523_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00118","author":"E Perrone","year":"2020","unstructured":"Perrone, E. et al. Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.00118 (2020).","journal-title":"Front. Oncol."},{"key":"1523_CR15","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","volume":"30","author":"Y Loriot","year":"2024","unstructured":"Loriot, Y. et al. Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer. Clin. Cancer Res. 30, 3179\u20133188 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1523_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol. 32, 1148\u20131156 (2021).","journal-title":"Ann. Oncol."},{"key":"1523_CR17","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates, J. T. et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11, 2436\u20132445 (2021).","journal-title":"Cancer Discov."},{"key":"1523_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00599-6","author":"A Ajkunic","year":"2024","unstructured":"Ajkunic, A. et al. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates. npj Precis. Oncol. https:\/\/doi.org\/10.1038\/s41698-024-00599-6 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1523_CR19","doi-asserted-by":"publisher","unstructured":"Morgenstern-Kaplan D., et al. Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. Oncologist. Published online. https:\/\/doi.org\/10.1093\/oncolo\/oyae168 (2024).","DOI":"10.1093\/oncolo\/oyae168"},{"key":"1523_CR20","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41589-019-0342-2","volume":"15","author":"CK Tsui","year":"2019","unstructured":"Tsui, C. K. et al. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat. Chem. Biol. 15, 949\u2013958 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"1523_CR21","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., Lorusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"1523_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41586-024-08244-9","volume":"637","author":"THH Coorens","year":"2025","unstructured":"Coorens, T. H. H. et al. The human and non-human primate developmental GTEx projects. Nature 637, 557\u2013564 (2025).","journal-title":"Nature"},{"key":"1523_CR23","doi-asserted-by":"crossref","unstructured":"Tomczak K., Czerwi\u0144ska P., Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contem. Oncol. 2015, 68\u201377 (2015)","DOI":"10.5114\/wo.2014.47136"},{"key":"1523_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-024-52437-1","author":"A Gehring","year":"2024","unstructured":"Gehring, A. et al. DNA demethylation and tri-methylation of H3K4 at the TACSTD2 promoter are complementary players for TROP2 regulation in colorectal cancer cells. Sci. Rep. https:\/\/doi.org\/10.1038\/S41598-024-52437-1 (2024).","journal-title":"Sci. Rep."},{"key":"1523_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/S41523-023-00573-8","author":"M Zhao","year":"2023","unstructured":"Zhao, M. et al. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. npj Breast Cancer https:\/\/doi.org\/10.1038\/S41523-023-00573-8 (2023).","journal-title":"npj Breast Cancer"},{"key":"1523_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4132\/jptm.2017.10.17","volume":"52","author":"JS Kong","year":"2018","unstructured":"Kong, J. S. et al. The significance of TROP2 expression in predicting BRAF mutations in papillary thyroid carcinoma. J. Pathol. Transl. Med. 52, 14\u201320 (2018).","journal-title":"J. Pathol. Transl. Med."},{"key":"1523_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41420-025-02429-5","volume":"11","author":"Q Yin","year":"2025","unstructured":"Yin, Q. et al. Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates. Cell Death Discov. 11, 144 (2025).","journal-title":"Cell Death Discov."},{"key":"1523_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2024.04.022","volume":"187","author":"Y Chiba","year":"2024","unstructured":"Chiba, Y. et al. Trop-2 expression and the tumor immune microenvironment in cervical cancer. Gynecol. Oncol. 187, 51\u201357 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1523_CR29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede, A. et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 30, 779\u2013785 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1523_CR30","doi-asserted-by":"publisher","first-page":"e012265","DOI":"10.1136\/jitc-2025-012265","volume":"14","author":"B Wu","year":"2026","unstructured":"Wu, B. et al. TROP2\/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. J. Immunother. Cancer 14, e012265 (2026).","journal-title":"J. Immunother. Cancer"},{"key":"1523_CR31","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00720-2","author":"B Yao","year":"2022","unstructured":"Yao, B. et al. Selection of payloads for antibody-drug conjugates targeting ubiquitously expressed tumor-associated antigens: a case study. AAPS J. https:\/\/doi.org\/10.1208\/s12248-022-00720-2 (2022).","journal-title":"AAPS J."},{"key":"1523_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","author":"LC Tsao","year":"2025","unstructured":"Tsao, L. C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-025-58266-8 (2025).","journal-title":"Nat. Commun."},{"key":"1523_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02037","author":"T Jako\u0161","year":"2019","unstructured":"Jako\u0161, T., Pi\u0161lar, A., Jewett, A. & Kos, J. Cysteine cathepsins in tumor-associated immune cells. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02037 (2019).","journal-title":"Front. Immunol."},{"key":"1523_CR34","doi-asserted-by":"publisher","unstructured":"Vogel, M., Colombo, R. & Tarantino P. Beyond the guided missile paradigm: embracing the complexity of antibody-drug conjugates. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-01235 (2025).","DOI":"10.1200\/JCO-25-01235"},{"key":"1523_CR35","doi-asserted-by":"publisher","unstructured":"Cursano, G. et al. Inter-assay variability of TROP2 immunohistochemistry in triple-negative breast cancer. Mol. Diagn Ther. https:\/\/doi.org\/10.1007\/S40291-025-00814-5\/FIGURES\/3 (2025).","DOI":"10.1007\/S40291-025-00814-5\/FIGURES\/3"},{"key":"1523_CR36","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1158\/1538-7445.AM2025-7149","volume":"85","author":"MS Sung","year":"2025","unstructured":"Sung, M. S. et al. Abstract 7149: the role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 normalized membrane ratio. Cancer Res. 85, 7149\u20137149 (2025).","journal-title":"Cancer Res."},{"key":"1523_CR37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1158\/1078-0432.CCR-24-1948","volume":"31","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Antitumor activity and biomarker analysis for TROP2 antibody\u2013drug conjugate datopotamab deruxtecan in patient-derived breast cancer xenograft models. Clin. Cancer Res. 31, 573 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1523_CR38","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MC Garassino","year":"2024","unstructured":"Garassino, M. C. et al. PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01. J. Thorac. Oncol. 19, S2\u2013S3 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1523_CR39","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.1016\/S1556-0864(25)00549-0","volume":"20","author":"YL Wu","year":"2025","unstructured":"Wu, Y. L. et al. 357P: Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced\/metastatic non-small cell lung cancer (a\/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02. J. Thorac. Oncol. 20, S212\u2013S213 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"1523_CR40","doi-asserted-by":"publisher","unstructured":"Jiang, D. et al. [68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. Eur. J. Nucl. Med. Mol. Imaging. https:\/\/doi.org\/10.1007\/s00259-025-07326-8 (2025).","DOI":"10.1007\/s00259-025-07326-8"},{"key":"1523_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-022-05954-y","volume":"50","author":"C Li","year":"2022","unstructured":"Li, C. et al. Theranostic application of 64Cu\/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur. J. Nucl. Med Mol. Imaging 50, 168\u2013183 (2022).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"1523_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41181-023-00235-x","volume":"9","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Preclinical evaluation of the theranostic potential of 89Zr\/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model. EJNMMI Radiopharm. Chem. 9, 5 (2024).","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"1523_CR43","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"1523_CR44","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1523_CR45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416.e11 (2018).","journal-title":"Cell"},{"key":"1523_CR46","doi-asserted-by":"publisher","unstructured":"Tyler, M. et al. The curated cancer cell Atlas provides a comprehensive characterization of tumors at single-cell resolution. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-025-00957-8 (2025).","DOI":"10.1038\/s43018-025-00957-8"},{"key":"1523_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2169","author":"M Karlsson","year":"2021","unstructured":"Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abh2169 (2021).","journal-title":"Sci. Adv."},{"key":"1523_CR48","doi-asserted-by":"publisher","first-page":"D948","DOI":"10.1093\/nar\/gkae1071","volume":"53","author":"SC Dyer","year":"2025","unstructured":"Dyer, S. C. et al. Ensembl 2025. Nucleic Acids Res. 53, D948\u2013D957 (2025).","journal-title":"Nucleic Acids Res."},{"key":"1523_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0531-8","volume":"10","author":"D Tamborero","year":"2018","unstructured":"Tamborero, D. et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 10, 25 (2018).","journal-title":"Genome Med."},{"key":"1523_CR50","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","volume":"79","author":"A Jimenez-Sanchez","year":"2019","unstructured":"Jimenez-Sanchez, A., Cast, O. & Miller, M. L. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 79, 6238\u20136246 (2019).","journal-title":"Cancer Res."},{"key":"1523_CR51","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1523_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2435-4","author":"M Foroutan","year":"2018","unstructured":"Foroutan, M. et al. Single sample scoring of molecular phenotypes. BMC Bioinform. https:\/\/doi.org\/10.1186\/s12859-018-2435-4 (2018).","journal-title":"BMC Bioinform."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01523-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:03:30Z","timestamp":1781514210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01523-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01523-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GN reports travel, accommodation, and expenses for scientific meetings from Eli Lilly, Sanofi, and MSD. GV reports support for travel from Eli Lilly, Pfizer, and AstraZeneca; advisory board participation for Pfizer and Novartis; and speaker fees from Daiichi Sankyo and Eli Lilly. MMN reports travel, accommodation, and expenses for scientific meetings from Eli Lilly and Daiichi Sankyo. CB reports grants from the American-Italian Cancer Foundation during the conduct of the study, as well as other support from Gilead Sciences, Daiichi Sankyo, and Eli Lilly and Company, and personal fees from MSD outside the submitted work. LL reports personal fees for consultancy, advisory board participation, and speaker bureau activities from AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Gilead, Exact Sciences, Helsinn, Roche, Italfarmaco, Accord, Eisai, and Takeda; and support for attending meetings from Gilead, Accord, Helsinn, Roche, and Daiichi Sankyo. MM reports travel grants from Gilead and Eli Lilly. MP reports travel, accommodation, and expenses from Novartis and Eli Lilly. CC reports consultancy, advisory roles, and speaker bureau participation for Pfizer, Novartis, Eli Lilly, Roche, MSD, Daiichi Sankyo, AstraZeneca, Gilead, and Menarini Stemline. CZ reports travel, accommodation, and expenses for scientific meetings from Gilead. FP reports support for attending meetings from Menarini, Gilead, Pfizer, and Eli Lilly. AC reports support for attending meetings from Pfizer, Eli Lilly, and Novartis. JP reports advisory roles for Eli Lilly, Roche, Eisai, MSD, Daiichi Sankyo, AstraZeneca, Seattle Genetics, and Gilead; and travel expenses from Roche and Daiichi Sankyo. JC reports consultancy, advisory board participation, and honoraria from Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Merck Sharp & Dohme, Gilead, Eisai, Seattle Genetics, Menarini, Boehringer Ingelheim, Clovis Oncology, Jazz Pharmaceuticals, AbbVie, BioNTech, Zymeworks, Biocon, Circle Pharma, Delcath Systems, Hexagon Bio, Hibercell, BioInvent, Gemoab, Leuko, Bioasis, Ellipses, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, BridgeBio, Bliss Biopharmaceutical, Stemline Therapeutics, and Zuellig Pharma.Research funding to the institution has been received from Roche, F. Hoffmann\u2013La Roche, AstraZeneca, Ariad Pharmaceuticals, Baxalta GmbH\/Servier Affaires, Bayer Healthcare, Eisai, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, IQVIA, and Queen Mary University of London.Support for travel, accommodation, and meeting expenses has been received from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, AstraZeneca, Gilead, Merck Sharp & Dohme, and Stemline Therapeutics.Stock ownership is reported in MAJ3 Capital and Leuko (relative).JC is a co-inventor on patents related to pharmaceutical combinations of a PI3K inhibitor and a microtubule-destabilizing agent (WO 2014\/199294 A; issued) and HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy (US 2019\/0338368 A1; licensed). LP reports consultancy, advisory board participation, and honoraria from Merck & Co., AstraZeneca, Bristol Myers Squibb, Agendia, Radionetics, Natera, and Personalis. Research funding to the institution has been received from Merck & Co., AstraZeneca, Bristol Myers Squibb, Pfizer, Menarini, Natera, Exact Sciences, Personalis, and Agendia. Stock ownership is reported in Ataraxis. LG reports advisory board participation and consultancy for AstraZeneca, Roche, Synaffix, Zymeworks, Daiichi Sankyo, BeiGene, Revolution Medicines, Menarini Ricerche, and Denali Therapeutics Inc; and is a co-inventor of European Patent Applications No. 12195182.6 and 12196177.5 titled \u201cPD-L1 expression in anti-HER2 therapy\u201d (Roche; no compensation provided). GB reports personal fees for consultancy, honoraria, and advisory roles from AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Roche, MSD, Gilead, Menarini, Exact Sciences, Seagen, Helsinn, Takeda, and Amgen. MD reports travel expenses from Insight Molecular Diagnostics. The other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}